These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 10511836)
41. Incidence and costs of cardiometabolic conditions in patients with schizophrenia treated with antipsychotic medications. Jerrell JM; McIntyre RS; Tripathi A Clin Schizophr Relat Psychoses; 2010 Oct; 4(3):161-8. PubMed ID: 20880826 [TBL] [Abstract][Full Text] [Related]
42. Influence of body mass index on prescribing costs and potential cost savings of a weight management programme in primary care. Counterweight Project Team J Health Serv Res Policy; 2008 Jul; 13(3):158-66. PubMed ID: 18573765 [TBL] [Abstract][Full Text] [Related]
43. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. Gregg EW; Cheng YJ; Cadwell BL; Imperatore G; Williams DE; Flegal KM; Narayan KM; Williamson DF JAMA; 2005 Apr; 293(15):1868-74. PubMed ID: 15840861 [TBL] [Abstract][Full Text] [Related]
44. Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany. Brennan A; Ara R; Sterz R; Matiba B; Bergemann R Eur J Health Econ; 2006 Dec; 7(4):276-84. PubMed ID: 17063345 [TBL] [Abstract][Full Text] [Related]
45. Determining the cost of obesity and its common comorbidities from a commercial claims database. Padula WV; Allen RR; Nair KV Clin Obes; 2014 Feb; 4(1):53-8. PubMed ID: 25425133 [TBL] [Abstract][Full Text] [Related]
46. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. Anderson JW; Kendall CW; Jenkins DJ J Am Coll Nutr; 2003 Oct; 22(5):331-9. PubMed ID: 14559925 [TBL] [Abstract][Full Text] [Related]
47. Expected gains in life expectancy from various coronary heart disease risk factor modifications. Tsevat J; Weinstein MC; Williams LW; Tosteson AN; Goldman L Circulation; 1991 Apr; 83(4):1194-201. PubMed ID: 2013141 [TBL] [Abstract][Full Text] [Related]
48. Incorporating future costs in medical cost-effectiveness analysis: implications for the cost-effectiveness of the treatment of hypertension. Johannesson M; Meltzer D; O'Conor RM Med Decis Making; 1997; 17(4):382-9. PubMed ID: 9343796 [TBL] [Abstract][Full Text] [Related]
49. Weight-related increases in hypertension, hypercholesterolemia, and diabetes risk in normal weight male and female runners. Williams PT; Hoffman K; La I Arterioscler Thromb Vasc Biol; 2007 Aug; 27(8):1811-9. PubMed ID: 17510467 [TBL] [Abstract][Full Text] [Related]
50. Cardiometabolic Risk Factors among Severely Obese Children and Adolescents in the United States, 1999-2012. Li L; Pérez A; Wu LT; Ranjit N; Brown HS; Kelder SH Child Obes; 2016 Feb; 12(1):12-9. PubMed ID: 26785314 [TBL] [Abstract][Full Text] [Related]
51. Health and economic burden of the projected obesity trends in the USA and the UK. Wang YC; McPherson K; Marsh T; Gortmaker SL; Brown M Lancet; 2011 Aug; 378(9793):815-25. PubMed ID: 21872750 [TBL] [Abstract][Full Text] [Related]
52. An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands. Boersma C; Carides GW; Atthobari J; Voors AA; Postma MJ Clin Ther; 2007 May; 29(5):963-971. PubMed ID: 17697915 [TBL] [Abstract][Full Text] [Related]
53. Cardiorespiratory fitness in young adulthood and the development of cardiovascular disease risk factors. Carnethon MR; Gidding SS; Nehgme R; Sidney S; Jacobs DR; Liu K JAMA; 2003 Dec; 290(23):3092-100. PubMed ID: 14679272 [TBL] [Abstract][Full Text] [Related]
54. Are healthcare costs from obesity associated with body mass index, comorbidity or depression? Cohort study using electronic health records. Rudisill C; Charlton J; Booth HP; Gulliford MC Clin Obes; 2016 Jun; 6(3):225-31. PubMed ID: 27097821 [TBL] [Abstract][Full Text] [Related]
55. Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain. Shearer AT; Bagust A; Ampudia-Blasco FJ; Martínez-Lage Alvarez B; Pérez Escolano I; París G Pharmacoeconomics; 2006; 24 Suppl 1():49-59. PubMed ID: 16800162 [TBL] [Abstract][Full Text] [Related]
56. Association of obesity with risk of coronary heart disease: findings from the National Health and Nutrition Examination Survey, 1999-2006. Nguyen NT; Nguyen XM; Wooldridge JB; Slone JA; Lane JS Surg Obes Relat Dis; 2010; 6(5):465-9. PubMed ID: 20870177 [TBL] [Abstract][Full Text] [Related]
57. Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization? Grover SA; Coupal L; Zowall H Hypertension; 2005 Jan; 45(1):92-7. PubMed ID: 15545508 [TBL] [Abstract][Full Text] [Related]
58. Prevalence of cardiovascular risk factors among 28,000 employees. Scheerbaum M; Langenbach C; Scheerbaum P; Heidemann F; Rieß HC; Heigel H; Debus SE; Behrendt CA Vasa; 2017 May; 46(3):203-210. PubMed ID: 28156256 [TBL] [Abstract][Full Text] [Related]
59. Evaluation of cardiovascular risk factors, events, and costs across four BMI categories. Brixner DI; Bron M; Bellows BK; Ye X; Yu J; Raparla S; Oderda GM Obesity (Silver Spring); 2013 Jun; 21(6):1284-92. PubMed ID: 23913737 [TBL] [Abstract][Full Text] [Related]
60. The Burden of Obesity on Diabetes in the United States: Medical Expenditure Panel Survey, 2008 to 2012. Leung MY; Carlsson NP; Colditz GA; Chang SH Value Health; 2017 Jan; 20(1):77-84. PubMed ID: 28212973 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]